It would be better for RGS to publish the results of their trial for peer review, rather than having to rely on their opinion.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025